BiotechTube

QR-010 + Placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis

Trial Timeline

Jun 1, 2015 → Sep 14, 2017

NCT ID
NCT02532764

About QR-010 + Placebo

QR-010 + Placebo is a phase 1/2 stage product being developed by ProQR for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02532764. Target conditions include Cystic Fibrosis.

What happened to similar drugs?

20 of 20 similar drugs in Cystic Fibrosis were approved

Approved (20) Terminated (7) Active (0)
✅CefiderocolShionogiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PancrelipaseAbbVieApproved
✅Tedizolid PO + Tedizolid IVMerckApproved
✅Alendronate + PlaceboMerckApproved
✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved
✅Ceftolozane/TazobactamMerckApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02532764Phase 1/2Completed

Competing Products

20 competing products in Cystic Fibrosis

See all competitors
ProductCompanyStageHype Score
VX-522 mRNA therapy + IVAModernaPhase 1/2
36
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
17
Enfortumab VedotinAstellas PharmaPhase 2
42
CefiderocolShionogiApproved
43
LenvatinibEisaiPhase 2
39
Lenvatinib + PembrolizumabEisaiPhase 2
39
CREONAbbVieApproved
43
Pancrelipase + PancrelipaseAbbVieApproved
43
Creon IR + Creon® (DR/GR)AbbViePhase 2
35
ABBV-CLS-628 + PlaceboAbbViePhase 2
42
Elagolix + PlaceboAbbViePhase 2
35
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222AbbViePhase 2
35
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119AbbViePhase 2
27
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
AZD5634 for inhalation + AZD5634 for infusionAstraZenecaPhase 1
29
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
40
AZD1236 + PlaceboAstraZenecaPhase 2
27
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
36
AZD9668 + AZD9668 Placebo equivalentAstraZenecaPhase 2
35